Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
Wegovy, Ozempic added to list of drugs where the federal government will try winning discounts from manufacturers.
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for the 15 additional drugs, which will be handled by the incoming administration, assure major savings for Americans.
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.
Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.
The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing the selection two weeks ahead of schedule.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback